Loading…
Autoimmunity and autoimmune co‐morbidities in psoriasis
Summary Psoriasis is characterized by widespread scaly erythematous plaques that cause significant physical and psychological burdens for the affected individuals. Accelerated inflammation driven by the tumour necrosis factor‐α/interleukin‐23/interleukin‐17 axis is now known to be the major mechanis...
Saved in:
Published in: | Immunology 2018-05, Vol.154 (1), p.21-27 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Summary
Psoriasis is characterized by widespread scaly erythematous plaques that cause significant physical and psychological burdens for the affected individuals. Accelerated inflammation driven by the tumour necrosis factor‐α/interleukin‐23/interleukin‐17 axis is now known to be the major mechanism in the development of psoriasis. In addition, psoriasis has an autoimmune nature that manifests as autoreactive T cells and is co‐morbid with other autoimmune diseases, such as autoimmune bullous diseases, vitiligo, alopecia and thyroiditis. In this article, we review the recent topics on autoimmunity and autoimmune co‐morbidities in psoriasis.
Psoriasis is driven by the tumour necrosis factor‐α/interleukin‐23/interleukin‐17 axis. It has an autoimmune nature and is also co‐morbid with other autoimmune diseases such as autoimmune bullous diseases, vitiligo, alopecia and thyroiditis. |
---|---|
ISSN: | 0019-2805 1365-2567 |
DOI: | 10.1111/imm.12891 |